Ausgabe 2/2014
Inhalt (22 Artikel)
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
Constance King, Henry Diaz, Darlene Barnard, David Barda, David Clawson, Wayne Blosser, Karen Cox, Sherry Guo, Mark Marshall
Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB
Weiguo Liu, Jinming Zhou, Guoyan Geng, Rongtuan Lin, Jian Hui Wu
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
Guru Sonpavde, Mingjun Wang, Leif E. Peterson, Helen Y. Wang, Teresa Joe, Martha P. Mims, Dov Kadmon, Michael M. Ittmann, Thomas M. Wheeler, Adrian P. Gee, Rong-Fu Wang, Teresa G. Hayes
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L. Bedard, Eric Xueyu Chen, Blaise A. Clarke, Ben Tran, Sebastien J. Hotte, Anastasios Stathis, Hal W. Hirte, Albiruni R. A. Razak, Michael Reedijk, Zhuo Chen, Brenda Cohen, Wen-Jiang Zhang, Lisa Wang, S. Percy Ivy, Malcolm J. Moore, Amit M. Oza, Lillian L. Siu, Elaine McWhirter
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma
R. C. Turkington, C. Purcell, C. R. James, J. Millar, E. Napier, D. Law, R. Gallagher, M. Morris, R. H. Wilson, M. M. Eatock
Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
Narikazu Boku, Kei Muro, Nozomu Machida, Satoshi Hashigaki, Nobuyuki Kimura, Mie Suzuki, Mariajose Lechuga, Yoshinori Miyata
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer
Changhoon Yoo, Min-Hee Ryu, Young-Soon Na, Baek-Yeol Ryoo, Chae-Won Lee, Jeheon Maeng, Se-Yeon Kim, Dong Hoe Koo, Inkeun Park, Yoon-Koo Kang
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer
Prasanth Ganesan, Sarina Piha-Paul, Aung Naing, Gerald Falchook, Jennifer Wheler, Siqing Fu, David S. Hong, Razelle Kurzrock, Filip Janku, Shell Laday, Agop Y. Bedikian, Merrill Kies, Robert A. Wolff, Apostolia M. Tsimberidou
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study
J. Martín-Liberal, A. López-Pousa, J. Martín Broto, R. Cubedo, O. Gallego, E. Brendel, O. M. Tirado, X. García del Muro
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
William R. Schelman, Tabraiz A. Mohammed, Anne M. Traynor, Jill M. Kolesar, Rebecca M. Marnocha, Jens Eickhoff, Michael Keppen, Dona B. Alberti, George Wilding, Naoko Takebe, Glenn Liu
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study
Patricia M. LoRusso, Smitha Krishnamurthi, Hagop Youssoufian, Nancy Hall, Floyd Fox, Aruna Dontabhaktuni, Dmitri Grebennik, Scot Remick
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples
Vladimir Lazar, Nathalie Lassau, Guillaume Meurice, Yohann Loriot, Carol Peña, Christophe Massard, Caroline Robert, Thomas Robert, Marie-Aude Le Berre, Thierry de Baere, Philippe Dessen, Jean-Charles Soria, Jean-Pierre Armand
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
Dustin A. Deming, Jacob Ninan, Howard H. Bailey, Jill M. Kolesar, Jens Eickhoff, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Dona Alberti, Rebecca Marnocha, Igor Espinoza-Delgado, John Wright, George Wilding, William R. Schelman
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
John H. Strickler, Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, Alexander Starodub, Christy Arrowood, Sherri Haley, Kellen L. Meadows, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, S. David Hsu, S. Yousuf Zafar, Herbert I. Hurwitz
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
Woondong Jeong, Sook Ryun Park, Annamaria Rapisarda, Nicole Fer, Robert J. Kinders, Alice Chen, Giovanni Melillo, Baris Turkbey, Seth M. Steinberg, Peter Choyke, James H. Doroshow, Shivaani Kummar
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses
Wolfgang Uhl, Michael Zühlsdorf, Thomas Koernicke, Ulf Forssmann, Andreas Kovar
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Yoon-Koo Kang, Kei Muro, Min-Hee Ryu, Hirofumi Yasui, Tomohiro Nishina, Baek-Yeol Ryoo, Yukimasa Kamiya, Shiro Akinaga, Narikazu Boku
Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
Neelesh Sharma, Nathan Pennell, Myles Nickolich, Balazs Halmos, Patrick Ma, Tarek Mekhail, Pingfu Fu, Afshin Dowlati
A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis
Jae-Cheol Jo, Yong Sang Hong, Kyu-Pyo Kim, Jae-Lyun Lee, Jeeyun Lee, Young Suk Park, Sun Young Kim, Jin-Sook Ryu, Jong-Seok Lee, Tae Won Kim
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)
Carlos Alvarez-Fernandez, Quionia Perez-Arnillas, Lucrecia Ruiz-Echeverria, David Rodriguez-Rubi, Luisa Sanchez-Lorenzo, Walter Li-Torres, Marta Izquierdo-Manuel, Jose P. Berros, Maria Luque-Cabal, Paula Jimenez-Fonseca, Noemi Villanueva-Palicio, Emilio Esteban-Gonzalez
Low skeletal muscle is associated with toxicity in patients included in phase I trials
Sophie Cousin, A. Hollebecque, S. Koscielny, O. Mir, A. Varga, V. E. Baracos, J. C. Soria, S. Antoun
Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
Yu Sunakawa, Junji Furuse, Takuji Okusaka, Masafumi Ikeda, Fumio Nagashima, Hideki Ueno, Shuichi Mitsunaga, Kensei Hashizume, Yuichiro Ito, Yasutsuna Sasaki